Travere Therapeutics

Historical price data

Travere Therapeutics is a publicly traded biopharma company singularly focused on rare diseases, particularly in nephrology and metabolism. Its strategic pipeline includes the commercially available therapy for IgA nephropathy and late-stage investigational candidates for FSGS and classical homocystinuria, aiming to set new standards of care. The company operates with a deep sense of urgency, guided by its 'In Rare For Life' ethos and a leadership team that includes rare disease patients and survivors, fostering strong community and advocacy partnerships.

Travere's core approach is patient-centric drug development and commercialization in niche rare diseases, focusing on strategic target identification, late-stage clinical development, and integrated advocacy to support diagnosis and care.

14 drugs in pipeline, 5 in Phase 3

Total raised: $115M

In IgAN, Travere competes with other therapies like SGLT2 inhibitors and Novartis's atrasentan. In FSGS, it aims to be first-to-market against generic standards of care. For HCU, it faces little direct pharmacological competition. Differentiation is built on rare disease specialization, patient advocacy, and a comprehensive support ecosystem.